Fig. 2

EED inhibitors impair the migration of DC2.4 cells. A SRB analysis for the survival rate of DC2.4 upon treatment with different EED inhibitors at various concentrations (0, 0.32, 0.63, 1.25, 2.5, 5, 10, 20 or 40 μM) for 24 h. n = 3. * indicates a statistically difference when compared with 0 μM. B Western blotting analysis (left) and corresponding quantification (right) for the expression of H3K27me3 and EED in DC2.4 after treatment with A395 (5 μM), MAK683 (5 μM), EEDi-5285 (5 μM) or EED226 (10 μM) for 24 h. n = 3. C Scheme for transwell analysis of chemokines-triggered migration of DC2.4 after treating with LPS or different EED inhibitors. D Representative images (left) and statistics (right) for transwell analysis together with crystal violet staining in DC2.4 after treating with A395 (5 μM), MAK683 (5 μM), EEDi-5285 (5 μM) or EED226 (10 μM) for 24 h and LPS (50 ng/mL) for 6 h. Scale bar: 200 μm. n = 3. E Immunostaining of F-Actin (green) in DC2.4 after treating with A395 (5 μM), MAK683 (5 μM), EEDi-5285 (5 μM) or EED226 (10 μM) for 24 h and LPS (50 ng/mL) for 6 h. Scale bar: 10 μm. n = 3. F Western blotting analysis (left) and the corresponding quantification (right) for the expression of H3K27me3 in DC2.4 after transfection with HA-EED plasmid and treatment with A395 (5 μM), MAK683 (5 μM), EEDi-5285 (5 μM) or EED226 (10 μM) for 24 h and LPS (50 ng/mL) for 6 h. n = 3. G Scheme for transwell analysis of chemokines-triggered migration of DC2.4 after transfection with HA-EED plasmid and treatment with LPS and EED inhibitors. H Representative images (left) and statistics (right) for transwell analysis together with crystal violet staining in DC2.4 cells after transfection with HA-EED plasmid and treatment with A395 (5 μM), MAK683 (5 μM), EEDi-5285 (5 μM) or EED226 (10 μM) for 24 h and LPS (50 ng/mL) for 6 h. Scale bar: 200 μm. n = 3. Data are presented as mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant